John Schulte, Spectranetics’s president and CEO, said: “We are pleased to reach this settlement with Medtronic. This license validates our strong intellectual property position in the area of thrombus management with aspiration catheters.”
John Schulte, Spectranetics’s president and CEO, said: “We are pleased to reach this settlement with Medtronic. This license validates our strong intellectual property position in the area of thrombus management with aspiration catheters.”